ASX - By Stock
|
TLX Biotech |
Re:
Understanding Telix
|
|
Drian
|
769 |
348K |
12 |
06/05/24 |
06/05/24 |
ASX - By Stock
|
769
|
348K
|
12
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Understanding Telix
|
|
Drian
|
769 |
348K |
8 |
06/05/24 |
06/05/24 |
ASX - By Stock
|
769
|
348K
|
8
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Understanding Telix
|
|
Drian
|
769 |
348K |
13 |
22/04/24 |
22/04/24 |
ASX - By Stock
|
769
|
348K
|
13
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix Q1 2024 Revenue and Business Update
|
|
Drian
|
135 |
49K |
3 |
18/04/24 |
18/04/24 |
ASX - By Stock
|
135
|
49K
|
3
|
|
ASX - By Stock
|
CU6 |
Tlx buys ARTMS - effect on CU-64?
|
|
Drian
|
47 |
13K |
6 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
47
|
13K
|
6
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix to Acquire ARTMS (Isotope Production Platform)
|
|
Drian
|
43 |
17K |
1 |
05/03/24 |
05/03/24 |
ASX - By Stock
|
43
|
17K
|
1
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Understanding Telix
|
|
Drian
|
769 |
348K |
3 |
04/03/24 |
04/03/24 |
ASX - By Stock
|
769
|
348K
|
3
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix 2023 Full Year Results and Investor Webcast/Call
|
|
Drian
|
130 |
42K |
1 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
130
|
42K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix 2023 Full Year Results and Investor Webcast/Call
|
|
Drian
|
130 |
42K |
0 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
130
|
42K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix 2023 Full Year Results and Investor Webcast/Call
|
|
Drian
|
130 |
42K |
0 |
22/02/24 |
22/02/24 |
ASX - By Stock
|
130
|
42K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Presentation to Accompany QSAM Acquisition
|
|
Drian
|
23 |
12K |
4 |
15/02/24 |
15/02/24 |
ASX - By Stock
|
23
|
12K
|
4
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix Submits BLA for TLX250-CDx for Kidney Cancer Imaging
|
|
Drian
|
44 |
14K |
4 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
44
|
14K
|
4
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Telix Submits BLA for TLX250-CDx for Kidney Cancer Imaging
|
|
Drian
|
44 |
14K |
0 |
19/12/23 |
19/12/23 |
ASX - By Stock
|
44
|
14K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
TLX Chart
|
|
Drian
|
1.5K |
565K |
1 |
12/12/23 |
12/12/23 |
ASX - By Stock
|
1.5K
|
565K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
TLX Chart
|
|
Drian
|
1.5K |
565K |
0 |
12/12/23 |
12/12/23 |
ASX - By Stock
|
1.5K
|
565K
|
0
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: undetectable PSA level with Cu-67 SAR-bisPSMA
|
|
Drian
|
62 |
18K |
6 |
01/12/23 |
01/12/23 |
ASX - By Stock
|
62
|
18K
|
6
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Presentation to Accompany AI Development Program Update
|
|
Drian
|
62 |
28K |
5 |
10/11/23 |
10/11/23 |
ASX - By Stock
|
62
|
28K
|
5
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Presentation to Accompany AI Development Program Update
|
|
Drian
|
62 |
28K |
0 |
09/11/23 |
09/11/23 |
ASX - By Stock
|
62
|
28K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Presentation to Accompany AI Development Program Update
|
|
Drian
|
62 |
28K |
0 |
09/11/23 |
09/11/23 |
ASX - By Stock
|
62
|
28K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Ann: Presentation to Accompany AI Development Program Update
|
|
Drian
|
62 |
28K |
0 |
09/11/23 |
09/11/23 |
ASX - By Stock
|
62
|
28K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
TLX Chart
|
|
Drian
|
1.5K |
565K |
14 |
23/10/23 |
23/10/23 |
ASX - By Stock
|
1.5K
|
565K
|
14
|
|
ASX - By Stock
|
TLX |
Re:
Eli Lily to acquire radio-harms company Point Biopharma for $US1.4 billion
|
|
Drian
|
10 |
4.5K |
4 |
05/10/23 |
05/10/23 |
ASX - By Stock
|
10
|
4.5K
|
4
|
|
ASX - By Stock
|
TLX |
Re:
Competition
|
|
Drian
|
254 |
114K |
3 |
22/09/23 |
22/09/23 |
ASX - By Stock
|
254
|
114K
|
3
|
|
ASX - By Stock
|
TLX |
Re:
Competition
|
|
Drian
|
254 |
114K |
0 |
22/09/23 |
22/09/23 |
ASX - By Stock
|
254
|
114K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Competition
|
|
Drian
|
254 |
114K |
0 |
22/09/23 |
22/09/23 |
ASX - By Stock
|
254
|
114K
|
0
|
|
ASX - By Stock
|
CU6 |
Re:
CU6 - General discussion
|
|
Drian
|
362 |
125K |
1 |
20/09/23 |
20/09/23 |
ASX - By Stock
|
362
|
125K
|
1
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Appendix 4E and Annual Report
|
|
Drian
|
31 |
12K |
2 |
07/09/23 |
07/09/23 |
ASX - By Stock
|
31
|
12K
|
2
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Appendix 4E and Annual Report
|
|
Drian
|
31 |
12K |
3 |
07/09/23 |
07/09/23 |
ASX - By Stock
|
31
|
12K
|
3
|
|
ASX - By Stock
|
OSL |
Re:
Ann: Appendix 4E and Annual Report
|
|
Drian
|
31 |
12K |
0 |
07/09/23 |
07/09/23 |
ASX - By Stock
|
31
|
12K
|
0
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Understanding Telix
|
|
Drian
|
769 |
348K |
10 |
02/09/23 |
02/09/23 |
ASX - By Stock
|
769
|
348K
|
10
|
|
ASX - By Stock
|
CU6 |
Re:
ASX: CU6 Outlook.
|
|
Drian
|
71 |
33K |
2 |
25/08/23 |
25/08/23 |
ASX - By Stock
|
71
|
33K
|
2
|
|
ASX - By Stock
|
CU6 |
Re:
ASX: CU6 Outlook.
|
|
Drian
|
71 |
33K |
12 |
25/08/23 |
25/08/23 |
ASX - By Stock
|
71
|
33K
|
12
|
|
ASX - By Stock
|
TLX |
Re:
Ann: 1H 2023 Results Presentation
|
|
Drian
|
102 |
29K |
4 |
24/08/23 |
24/08/23 |
ASX - By Stock
|
102
|
29K
|
4
|
|
ASX - By Stock
|
TLX |
Re:
Ann: 1H 2023 Results Presentation
|
|
Drian
|
102 |
29K |
10 |
24/08/23 |
24/08/23 |
ASX - By Stock
|
102
|
29K
|
10
|
|
ASX - By Stock
|
RAD |
Re:
Ann: EGM Presentation
|
|
Drian
|
13 |
4.7K |
1 |
18/08/23 |
18/08/23 |
ASX - By Stock
|
13
|
4.7K
|
1
|
|
ASX - By Stock
|
RAD |
Re:
Ann: EGM Presentation
|
|
Drian
|
13 |
4.7K |
2 |
18/08/23 |
18/08/23 |
ASX - By Stock
|
13
|
4.7K
|
2
|
|
ASX - By Stock
|
RAD |
Re:
Ann: EGM Presentation
|
|
Drian
|
13 |
4.7K |
2 |
18/08/23 |
18/08/23 |
ASX - By Stock
|
13
|
4.7K
|
2
|
|
ASX - By Stock
|
RAD |
Re:
Ann: EGM Presentation
|
|
Drian
|
13 |
4.7K |
2 |
18/08/23 |
18/08/23 |
ASX - By Stock
|
13
|
4.7K
|
2
|
|
ASX - By Stock
|
TLX |
Re:
review of radiopharma companies
|
|
Drian
|
9 |
2.4K |
3 |
17/08/23 |
17/08/23 |
ASX - By Stock
|
9
|
2.4K
|
3
|
|
ASX - By Stock
|
TLX |
Re:
review of radiopharma companies
|
|
Drian
|
9 |
2.4K |
0 |
17/08/23 |
17/08/23 |
ASX - By Stock
|
9
|
2.4K
|
0
|
|
ASX - By Stock
|
TLX |
review of radiopharma companies
|
|
Drian
|
9 |
2.4K |
1 |
16/08/23 |
16/08/23 |
ASX - By Stock
|
9
|
2.4K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Short Term trading, analysis and TLX noise - No investors keep out
|
|
Drian
|
380 |
113K |
0 |
14/08/23 |
14/08/23 |
ASX - By Stock
|
380
|
113K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
Short Term trading, analysis and TLX noise - No investors keep out
|
|
Drian
|
380 |
113K |
6 |
12/08/23 |
12/08/23 |
ASX - By Stock
|
380
|
113K
|
6
|
|
ASX - By Stock
|
TLX |
Re:
TLX Chart
|
|
Drian
|
1.5K |
565K |
4 |
09/08/23 |
09/08/23 |
ASX - By Stock
|
1.5K
|
565K
|
4
|
|
ASX - By Stock
|
CU6 |
Re:
Ann: Clarity Bolsters Antibody Pre-Targeting with IP from MSK
|
|
Drian
|
40 |
9.4K |
4 |
07/08/23 |
07/08/23 |
ASX - By Stock
|
40
|
9.4K
|
4
|
|
ASX - By Stock
|
TLX |
Re:
Competition
|
|
Drian
|
254 |
114K |
0 |
02/08/23 |
02/08/23 |
ASX - By Stock
|
254
|
114K
|
0
|
|
ASX - By Stock
|
TLX Biotech |
Re:
Understanding Telix
|
|
Drian
|
769 |
348K |
4 |
28/07/23 |
28/07/23 |
ASX - By Stock
|
769
|
348K
|
4
|
|
ASX - By Stock
|
PTX |
Re:
Ann: June 2023 Quarterly Update and Appendix 4C
|
|
Drian
|
45 |
17K |
24 |
27/07/23 |
27/07/23 |
ASX - By Stock
|
45
|
17K
|
24
|
|
ASX - By Stock
|
TLX |
Re:
12 month price targets
|
|
Drian
|
29 |
12K |
2 |
25/07/23 |
25/07/23 |
ASX - By Stock
|
29
|
12K
|
2
|
|
ASX - By Stock
|
TLX |
EU approval
|
|
Drian
|
2 |
891 |
1 |
20/07/23 |
20/07/23 |
ASX - By Stock
|
2
|
891
|
1
|
|